5th DCVA Translational Cardiovascular Research Meeting

“Together we beat as one”

Program Thursday 24 June 2021

08:30

Registration Opens

09:30 - 10.30

Plenary Opening the board of NLHI Dutch CardioVascular Alliance Wiek van Gilst (DCVA) Keynote Lecture: "Biomarkers in cardiovascular disease: what is the next step?” Professor Naveed Sattar (University of Glasgow)

10:30 – 10:45

Short Break

10:45 – 11:45

Fellowships Candidates for Fellowships present themselves: 1. Non-invasive assessment of patient-specific conduction pathways and associated arrhythmic vulnerability by combining 3D anatomical substrate characterization and electrical simulations Pranav Bhagirath (Amsterdam) 2. Tip the scale: The effect of medications on cell-to-cell variability in hypertrophic cardiomyopathy Jiayi Pei (Utrecht) 3. Epicardial fat as future therapeutic target for Cardiovascular Disease Irene van Blokland (Groningen) 4. Applications of mobile health in atrial fibrillation screening programs Rachel van der Velden (Maastricht)

11:45 – 12:00 Public Private Partnerships in Health & Care Carmen van Vilsteren, Health~Holland

11:45 – 12.00 Non-dilutive funding for (clinical) research and innovations Nawal Bahia El Idrissi, Catalyze

12.00 – 13.00

Lunch and online posters: During lunch you are invited to take a look at the posters which are presented on our website.

13:00 – 14:30

Workshop Y@H Personal media strategy – a quick guide into the world of social and traditional media

13:00 – 14:30

Session 1: Heart failure with preserved ejection fraction HFpEF Chairs: Rudolf de Boer (Groningen) & Stephane Heymans (Maastricht) 1. New algorithms for HFpEF diagnostics. Vanessa van Empel (Maastricht) 2. The new HFpEF scores: what’s the pathophysiology behind it? Carsten Tschöpe (Berlin, Germany) 3. HFpEF: current phase I and II trials Louis Handoko (Amsterdam) 4. Large animal models of HFpEF Daphne Merkus (Rotterdam and Munich, Germany) 5. Deltaplan Hartfalen Steven Chamuleau (Amsterdam)

13:00 – 14:30

Session 2: New Models: in-vivo, in-vitro, in-silico, on-the-chip: Vesicles Chairs: Leon Schurgers (Maastricht) & Andries van der Meer (Twente) 1. Small animal model for stroke Rick Dijkhuizen (Utrecht) 2. Large animal model for stroke Heleen van Beusekom (Rotterdam) 3. Plaque-on-a-chip: a model to understand plaque ruptur Kim van der Heiden (Rotterdam) 4. Novel in vitro organ on a chip and 2D assays to test impact human plasma-derived circulating factors on EC function Vincent van Duinen (Leiden) 5. Diabetic nephropathy alters the distribution of circulating angiogenic microRNAs among extracellular vesicles, HDL, and Ago-2 Roel Bijkerk (Leiden) 6. Studying the right heart myocardium in pulmonary hypertension using 3D engineered heart tissue Aida Llucià Valldeperas (Leiden)

13:00 – 14:30

Session 3: DNA biomarkers for disease risk prediction Chairs: Jessica van Setten (Utrecht) & Arthur Wilde (Amsterdam) 1. Polygenic risk scores in complex cardiovascular disorders Steve Lubitz (Boston, US) 2. Opposing common variant contributions to HCM and DCM Rafik Tadros (Montreal, Canada) 3. Different genetic architectures of inherited cardiac

arrhythmias Connie Bezzina (Amsterdam) 4. SCN5A founder mutations in Limburg Monika Stoll (Maastricht) 5. Rare variants as a cause of atrial fibrillation Peter van Tintelen (Utrecht) 6. Detection of two new DNA/chromatin regions increasing DCM risk Sophie Garnier (Paris, France)

13:00 – 14:30

Session 4: COVID-19 Chairs: Roland van Kimmenade (Nijmegen) & Marie-José Goumans (Leiden) 1. Contribution of inflammatory mechanisms of cardiovascular disease to COVID-19 comorbidityTomasz Guzik (Glasgow, UK) 2. COVID- The endothelium on the rackJurjan Aman (Amsterdam) 3. The role of cardiovascular disease in the COVID-19 pandemic - most important insights obtained from the CAPACITY-COVID registryMarijke Linschoten (Utrecht) 4.COVID-19 associated mechanisms of hypercoagulabilityMagdi Nagy (Maastricht) 5.SARS-CoV-2 and myocardial involvement in the elite athlete’s heart: Olympic showstopper or food for thought?Harald Jørstad (Amsterdam) 6.Modeling and attacking sars-cov2-induced cardiovascular disease with organs on chipRobert Passier (Twente)

13:00 – 14:30

Session 5: Early recognition and early intervention: AF and comorbidities Chairs: Michiel Rienstra (Groningen) & Natasja de Groot (Rotterdam) 1. Ex vivo heart perfusion: a platform for patient-tailored therapy of heart failure and atrial fibrillation Yannick Taverne (Rotterdam) 2. Atrial fibrillation: The electrical fingerprint Mathijs van Schie (Rotterdam) 3. Atrial fibrillation: The molecular fingerprint Kennedy Ramos (Amsterdam) 4. The role of circulating non-coding RNAs in vascular homeostasis and disease Anton Jan van Zonneveld (Leiden) 5. When is the optimal moment to cardiovert AF? Nikki Pluymakers (Maastricht) 6. Population models of AF, a new tool to study effects of comorbidities and responsiveness to therapy Jordi Heijman (Maastricht)

14:30 – 15:00

Coffee break

15.00 – 15.45 Einthoven Prizes 3 candidates max. 10 minutes p.p. Potential detrimental effects of exercise on the heart Vincent Aengevaeren (Nijmegen) Diagnostic evaluation of chest pain: The role of non-invasive cardiac imaging Martijn Smulders (Maastricht) Dissecting genetic risk in common and rare inherited disorders Najim Lahrouchi (Amsterdam)

15:45 – 17:15

Workshop Y@H Networking – how to find, approach, and connect with project partners, mentors, and future employers

15:45 – 17:15

Session 6: Early recognition and early intervention: Modern strategies Chairs: Joline Beulens (Amsterdam) & Jaap Kappelle (Utrecht) 1. Prehospital stroke triage with devices or decision tools. Bob Roozenbeek (Rotterdam) 2. Speeding up time to endovasculair stroke intervention: Results MR CLEAN NoIV trial. Bart Emmer (Amsterdam) 3.The importance of physical examination Frans Rutten (Utrecht) 4. Cardiac biomarkers in primary care Rudolf de Boer (Groningen) 5. Early diagnosis of cardiovascular diseases in primary care Amy Groenewegen (Utrecht) and Victor Zwartkruis (Groningen)

15:45 – 17:15

Session 7: Diagnostic tools and valorization Chairs: Michiel Rienstra (Groningen) & Jordi Heijman (Maastricht) 1. Tricks and tips in valorisation of AI solutions Henk Marquering (Amsterdam) 2. Deep learning for image biomarker extraction / prediction of outcome Theo van Walsum (Rotterdam) 3. Heart sounds: new wine in new bags for continuous disease monitoring Frits Prinzen (Maastricht) 4. ECG for characterization of the AF substrate Stef Zeemering (Maastricht) 5. Social distancing in AF management: TeleCheck AF Dominik Linz (Maastricht) 6. Towards classification of AF with implatable devices: data from RACE V Bao-Oanh Ngyen (Groningen)

15:45 – 17:15

Session 8: New Models: in-vivo, in-vitro, in-silico, on-the-chip: Heart

Chairs: Miranda Nabben (Maastricht) & Daan Westenbrink (Groningen) 1. Models to study allelic imbalance in cardiomyopathies on a single cell level Judith Montag (Hannover, Germany) 2. Modeling genetic heart disease in mouse models Nienke Stege(Groningen) 3. High-throughput studies in iPSC-derived cardiomyocytes Rafeeh Soleimanidinani (Amsterdam) 4. Zebrafish to model pediatric cardiomyopathy Judith Verhagen (Rotterdam) 5. Naturally occurring canine and feline cardiomyopathy models Frank van Steenbeek (Utrecht) 6. Engineered heart tissue modeling Edgar Nollet (Amsterdam)

15:45 – 17:15

Session 9: Sex-differences in cardiovascular disease Chairs: Vanessa van Empel (Maastricht) & Emma Louise Robinson (University of Colorado USA) 1. Sex-differences in atherosclerosis: what’s behind? Hester den Ruijter (Utrecht) 2. Age- and sex-specific differences in atherosclerotic plaque composition Marie de Bakker (Rotterdam) 3. Sex-differences in atrial fibrillation mechanisms Ulrich Schotten (Maastricht) 4. Sex-differences in the vascular function and thrombogenesis Antoinette Maassen van den Brink (Rotterdam) 5. Sex-differences in right heart adaptation to pulmonary hypertension Frances de Man (Amsterdam) 6. Sex differences in lipid metabolism Jeanine Roeters van Lennep (Rotterdam)

15:45 – 17:15

Session 10: Omics in atherosclerosis Chairs: Johan Kuiper (Leiden) & Sander van der Laan (Utrecht) 1. The paradox of IL1b, perivascular cell inflammation, and atherosclerosis Gary Owens (Virginia, US) 2. Single-cell analysis of T cells in the human atherosclerotic lesions Marie Depuydt (Leiden) 3. Transcriptomic based clustering of advanced atherosclerotic plaques: revisiting the lesion determinants that identify the vulnerable patient Michal Mokry (Utrecht)

Supported by:

4. Single-cell work on macrophages in human atherosclerosis Koen Prange (Amsterdam) 5. GWAS to single cell: Atherosclerotic disease susceptibility loci through the lens of single cells of advanced human atherosclerotic plaques Lotte Slenders (Utrecht) 6. Macrophage repressive histone modifications in atherosclerosis Annette Neele (Amsterdam)

17:15 – 17:30 Short Break

17:30 – 18.15 Keynote Lecture: Dr. Sean Wu (Stanford Cardiovascular Institute and Stanford University School of Medicine) “Dissecting the Complex Interplay Between Proliferation and Contractile Force Generation in Single Cardiomyocytes”.

18:15 – 18.30 Awarding Fellowships and Einthoven Prizes Closing by the board of NLHI

18:30 Social event Young@Heart